Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
245
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Predictors of short-term survival in Waldenström Macroglobulinemia

Gordon RuanDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-6969-9169
ORCID Icon,
Saurabh ZanwarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Jithma P. AbeykoonDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Stephen M. AnsellDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Morie GertzDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-3853-5196
ORCID Icon,
Ronald S. GoDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Eli MuchtarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0003-2210-2174
ORCID Icon,
Wilson I. GonsalvesDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Jonas PaludoDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Gita ThanarajasingamDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
David J. InwardsDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Carrie A. ThompsonDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Thomas M. HabermannDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Yi LinDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Grzegorz S. NowakowskiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Jose C. Villasboas BisnetoDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-2907-0809
ORCID Icon,
Angela DispenzieriDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0001-8780-9512
ORCID Icon,
Martha Q. LacyDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Francis K. BuadiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
David DingliDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Taxiarchis KourelisDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Rahma WarsameDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
S. Vincent RajkumarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Shaji KumarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0001-5336-261X
ORCID Icon &
Prashant KapoorDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4342-364X
ORCID Icon show all
Pages 2975-2979 | Received 15 Apr 2020, Accepted 20 Jun 2020, Published online: 14 Jul 2020

References

  • Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) guidelines 2016 . JAMA Oncol. 2017;3(9):1257–1265.
  • Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenstrom’s macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96(3):852–858.
  • Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–4170.
  • Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenstrom’s macroglobulinemia. Leukemia. 2019;33(11):2654–2661.
  • Hensel M, Brust J, Ploger C, et al. Excellent long-term survival of 170 patients with Waldenstrom’s macroglobulinemia treated in private oncology practices and a university hospital. Ann Hematol. 2012;91(12):1923–1928.
  • Zanwar S, Abeykoon JP, Ansell SM, et al. Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia. 2019;33(3):790–794.
  • Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom’s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res. 2010;34(10):1340–1343.
  • Dimopoulos MA, Kastritis E, Delimpassi S, et al. The International Prognostic Scoring System for Waldenstrom’s macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica. 2008;93(9):1420–1422.
  • Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):116–120.
  • Elsawa SF, Ansell SM. Cytokines in the microenvironment of Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):43–45.
  • Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32(1):107–114.
  • Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432–437.
  • Wu LW, Kao TW, Lin CM, et al. Examining the association between serum lactic dehydrogenase and all-cause mortality in patients with metabolic syndrome: a retrospective observational study. BMJ Open. 2016;6(5):e011186.
  • Kastritis E, Kyrtsonis MC, Morel P, et al. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica. 2015;100(11):e446–e449.
  • Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Br J Haematol. 2015;169(1):81–89.
  • Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440.
  • Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791–2796.
  • Abeykoon JP, Paludo J, King RL, et al. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. Am J Hematol. 2018;93(2):187–194.
  • Zanwar S, Abeykoon JP, Durot E, et al. Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom Macroglobulinemia. Am J Hematol. 2020;95(3):274–281.
  • Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018;97(8):1417–1425.
  • Auer RL, Owen RG, D'Sa S, et al. R2W: subcutaneous bortezomib, cyclophosphamide and rituximab (BCR) versus fludarabine, cyclophosphamide and rituximab (FCR) for initial therapy of Waldenstrőm''s macroglobulinemia: a randomised phase II study. Blood. 2016;128(22):618–618.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.